BofA lowered the firm’s price target on BioNTech (BNTX) to $143 from $147 and keeps a Buy rating on the shares after the company reported quarterly results, with FY24 COVID revenues coming in ...

BioNTech's Q4 2024 revenue surpassed estimates, totaling 1.19 billion euros. EPS reached 1.08 euros, vastly exceeding the expected 0.42 euros, showcasing strong earnings management. Revenue from ...

BioNTech is the Marketing Authorisation Holder for BNT162b2 (Original) and BNT162b2 Bivalent (Original/Omicron BA.4/BA.5) in the US, EU, UK, Canada, and other countries.

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you.

In the last three months, 4 analysts have published ratings on BioNTech BNTX, offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their ...

Reports Q4 revenue EUR 1.19B vs. EUR 1.48B last year. “From the very beginning, BioNTech’s (BNTX) vision has been to translate our science into survival and become an immunotherapy powerhouse.

BioNTech (NASDAQ:BNTX – Get Free Report) had its price target boosted by investment analysts at BMO Capital Markets from $130.00 to $143.00 in a report issued on Tuesday,Benzinga reports.